Shares of Biopharmx Corp (NYSEAMERICAN:BPMX) gapped up prior to trading on Thursday . The stock had previously closed at $0.33, but opened at $0.37. Biopharmx shares last traded at $0.42, with a volume of 2,343,218 shares trading hands.
Separately, Maxim Group set a $1.00 target price on Biopharmx and gave the stock a “buy” rating in a research note on Monday, September 9th.
The company’s 50 day moving average price is $0.35 and its 200 day moving average price is $0.51.
Biopharmx (NYSEAMERICAN:BPMX) last released its earnings results on Monday, September 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.11.
An institutional investor recently bought a new position in Biopharmx stock. Barclays PLC acquired a new stake in Biopharmx Corp (NYSEAMERICAN:BPMX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 175,000 shares of the biotechnology company’s stock, valued at approximately $58,000. Barclays PLC owned approximately 1.23% of Biopharmx at the end of the most recent quarter.
About Biopharmx (NYSEAMERICAN:BPMX)
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Featured Article: What is meant by holder of record?
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.